AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15588555 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg oral oxytetracycline (b.d.)
Number of subjects: 649
Study 15588555 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Benzamycin (3% erythromycin + 5% benzoyl peroxide)
Number of subjects: 649
Study 15588555 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Panoxyl Aquagel (5% benzoyl peroxide)
Number of subjects: 649
Study 15588555 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical erythromycin-containing regimens
Number of subjects: 649
Study 15588555 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antibiotics (minocycline and oxytetracycline)
Number of subjects: 649
Study 15588555 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical treatments (particularly benzoyl peroxide)
Number of subjects: 649
Study 15588555 — intervention group
Group type: COMPARATOR
Intervention: Active comparator group (topical Panoxyl Aquagel + oral placebo)
Number of subjects: 649
Study 11887546 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene, 20 micrograms intravenously
Number of subjects: 60
Study 11887546 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 60
Study 9707874 — intervention group
Group type: EXPERIMENTAL
Intervention: 200,000 IU vitamin A orally (Experimental)
Number of subjects: 100
Study 9707874 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 100
Study 8550863 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% tetracycline HCl from poly(D,L-lactide/glycolide) film strips (25 TTC-PLGA)
Number of subjects: 10
Study 8550863 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 10
Study 8550863 — intervention group
Group type: COMPARATOR
Intervention: Control strips without TTC (PLGA)
Number of subjects: 10
Study 8550863 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 10
Study 2136818 — intervention group
Group type: COMPARATOR
Intervention: GR32191 0.125 mg/kg
Number of subjects: 13
Study 2136818 — intervention group
Group type: COMPARATOR
Intervention: GR32191 0.25 mg/kg
Number of subjects: 13
Study 2136818 — intervention group
Group type: COMPARATOR
Intervention: GR32191 0.5 mg/kg
Number of subjects: 13
Study 2136818 — intervention group
Group type: COMPARATOR
Intervention: GR32191 1.0 mg/kg
Number of subjects: 13
Study 2136818 — intervention group
Group type: COMPARATOR
Intervention: GR32191 17.5 mg, three times daily
Number of subjects: 13
Study 2136818 — intervention group
Group type: COMPARATOR
Intervention: GR32191 17.5 mg, every 12 hours
Number of subjects: 13
Study 2136818 — intervention group
Group type: COMPARATOR
Intervention: GR32191
Number of subjects: 13
Study 30311402 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting insulin (insulin lispro) at 30°C and 10% humidity
Number of subjects: 10
Study 30311402 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting insulin (insulin lispro) at 15°C and 10% humidity
Number of subjects: 10
Study 28108426 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention (CSDH evacuation)
Number of subjects: 45
Study 28108426 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical management (spontaneous resolution)
Number of subjects: 45
Study 26122122 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 40
Study 26122122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23748324 — intervention group
Group type: EXPERIMENTAL
Intervention: TiUnite implants
Number of subjects: 44
Study 23748324 — intervention group
Group type: EXPERIMENTAL
Intervention: Machined implants
Number of subjects: 44
Study 21801549 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation with GP after invitation
Number of subjects: 285
Study 21801549 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation about child's weight
Number of subjects: 285
Study 21801549 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to specialist clinic
Number of subjects: 285
Study 21801549 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative weight-management referral
Number of subjects: 285
Study 19427979 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired cardiac CT scans
Number of subjects: 6814
Study 19427979 — intervention group
Group type: COMPARATOR
Intervention: Electron beam CT (EBCT)
Number of subjects: 6814
Study 19427979 — intervention group
Group type: EXPERIMENTAL
Intervention: MDCT cardiac scans
Number of subjects: 6814
Study 16886317 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-brushing by test subjects
Number of subjects: 0
Study 16886317 — intervention group
Group type: COMPARATOR
Intervention: Teeth brushed by a dental hygienist
Number of subjects: 0
Study 16886317 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of dentifrice
Number of subjects: 0
Study 14742390 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (1 mg/kg) under propofol anesthesia (PROP-F)
Number of subjects: 48
Study 14742390 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (1 mg/kg) under isoflurane anesthesia (ISO-F)
Number of subjects: 48
Study 14742390 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.1 mL/kg) under propofol anesthesia (PROP-S)
Number of subjects: 48
Study 14742390 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.1 mL/kg) under isoflurane anesthesia (ISO-S)
Number of subjects: 48
Study 11585482 — intervention group
Group type: EXPERIMENTAL
Intervention: Michigan's GDL program (implemented April 1, 1997)
Number of subjects: 0
Study 11585482 — intervention group
Group type: EXPERIMENTAL
Intervention: Michigan's GDL program
Number of subjects: 0
Study 9422896 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% nitrous oxide
Number of subjects: 12
Study 9422896 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 12
Study 8373897 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood samples from central catheters (internal jugular, caval, Shaldon, pulmonary artery)
Number of subjects: 60
Study 8373897 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood samples from internal jugular catheters
Number of subjects: 60
Study 8373897 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood samples from Shaldon catheters
Number of subjects: 60
Study 8373897 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood samples from peripheral venous cannulas
Number of subjects: 60
Study 8373897 — intervention group
Group type: COMPARATOR
Intervention: Blood samples from venipunctures
Number of subjects: 60
Study 3602098 — intervention group
Group type: EXPERIMENTAL
Intervention: Static visual fixations
Number of subjects: 35
Study 3602098 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccadic eye movements
Number of subjects: 35
Study 3602098 — intervention group
Group type: COMPARATOR
Intervention: Smooth pursuit eye movements
Number of subjects: 35
Study 31313068 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib at an intravenous dose of 1.3 mg/m2 twice weekly
Number of subjects: 28
Study 29302744 — intervention group
Group type: EXPERIMENTAL
Intervention: Situs inversus totalis (SIT) participants
Number of subjects: 15
Study 29302744 — intervention group
Group type: EXPERIMENTAL
Intervention: Situs inversus totalis (SIT) participants with primary ciliary dyskinesia (PCD)
Number of subjects: 15
Study 29302744 — intervention group
Group type: EXPERIMENTAL
Intervention: Situs inversus totalis (SIT) participants without primary ciliary dyskinesia (PCD)
Number of subjects: 15
Study 29302744 — intervention group
Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 15
Study 27919632 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59‐adjuvanted trivalent inactivated influenza vaccine (MF59‐aTIV) + 13‐valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 1149
Study 27919632 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 alone
Number of subjects: 1149
Study 27919632 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59‐aTIV alone
Number of subjects: 1149
Study 27919632 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant administration of MF59‐aTIV and PCV13
Number of subjects: 1149
Study 25099523 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (75 mg twice-weekly)
Number of subjects: 179
Study 25099523 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (8 mg/day)
Number of subjects: 179
Study 25099523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 24107437 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous zoledronate
Number of subjects: 0
Study 24107437 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibandronate
Number of subjects: 0
Study 24107437 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 0
Study 22105251 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 75
Study 22105251 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine
Number of subjects: 75
Study 22105251 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 75
Study 18192897 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (80 mg/day)
Number of subjects: 6
Study 18192897 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (40 mg/day)
Number of subjects: 6
Study 18192897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 18192897 — intervention group
Group type: EXPERIMENTAL
Intervention: E. coli lipopolysaccharide (LPS) infusion
Number of subjects: 6
Study 16729930 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin, 80 mg daily
Number of subjects: 9000
Study 16729930 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin, 20 or 40 mg daily
Number of subjects: 9000
Study 14515285 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal mesothelial cells
Number of subjects: 0
Study 11050702 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibalginadue Fast (test formulation)
Number of subjects: 18
Study 11050702 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (tablets)
Number of subjects: 18
Study 8792796 — intervention group
Group type: EXPERIMENTAL
Intervention: In-patient multidisciplinary rehabilitation program (21 days)
Number of subjects: 26
Study 8792796 — intervention group
Group type: COMPARATOR
Intervention: Out-patient physiotherapy designed by the patient's rheumatologist
Number of subjects: 26
Study 1613682 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam anaesthesia
Number of subjects: 12
Study 1613682 — intervention group
Group type: COMPARATOR
Intervention: Thiopental anaesthesia
Number of subjects: 12
Study 6486124 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 40 mg daily
Number of subjects: 122
Study 6486124 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine 86 mg daily
Number of subjects: 122
Study 6486124 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 122
Study 6486124 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (30 to 90 mg)
Number of subjects: 122
Study 31994006 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer mentor intervention for 12 weeks
Number of subjects: 48
Study 31994006 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer mentor intervention
Number of subjects: 48
Study 31994006 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment via social media
Number of subjects: 48
Study 29940668 — intervention group
Group type: EXPERIMENTAL
Intervention: HPβCD/Ang‐(1‐7)
Number of subjects: 0
Study 29940668 — intervention group
Group type: COMPARATOR
Intervention: HPβCD (Placebo)
Number of subjects: 0
Study 26542812 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg sublingual testosterone
Number of subjects: 42
Study 26542812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 24176251 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate start of the contraceptive patch (directly observed application of the patch in the clinic)
Number of subjects: 298
Study 24176251 — intervention group
Group type: COMPARATOR
Intervention: Delayed start of the contraceptive patch (beginning the Sunday after their abortion)
Number of subjects: 298
Study 23562564 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy (IMRT)
Number of subjects: 58
Study 23562564 — intervention group
Group type: COMPARATOR
Intervention: Three-dimensional conformal radiotherapy (3D-CRT)
Number of subjects: 58
Study 23562564 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT
Number of subjects: 58
Study 23562564 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IMRT and 3D-CRT
Number of subjects: 58
Study 23562564 — intervention group
Group type: COMPARATOR
Intervention: 3D-CRT
Number of subjects: 58
Study 21043553 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (Lysteda)
Number of subjects: 0
Study 21043553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18238972 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation medication discussion with obstetric providers
Number of subjects: 296
Study 18238972 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement
Number of subjects: 296
Study 18238972 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 296
Study 18238972 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication use during pregnancy
Number of subjects: 296
Study 18238972 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication discussion at postpartum visit
Number of subjects: 296
Study 18238972 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication use postpartum
Number of subjects: 296
Study 18238972 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with medication use
Number of subjects: 296
Study 16325968 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA supplementation (390-1170 mg/day)
Number of subjects: 17
Study 12755236 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplementation (60 mg elemental iron, 300 mg ferrous sulphate, 400 microg folic acid, Monday to Friday)
Number of subjects: 207
Study 12755236 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly supplementation (one tablet once a week every Monday)
Number of subjects: 207
Study 12755236 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medications)
Number of subjects: 207
Study 12755236 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplementation
Number of subjects: 207
Study 12755236 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly supplementation
Number of subjects: 207
Study 10939035 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (Respicur retard 400 mg)
Number of subjects: 30
Study 10939035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9174209 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 40
Study 9174209 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 40
Study 9174209 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-(R)-hydroxyclarithromycin
Number of subjects: 40
Study 8251272 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 20
Study 8251272 — intervention group
Group type: COMPARATOR
Intervention: Tracheal Intubation
Number of subjects: 20
Study 3080101 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion
Number of subjects: 12
Study 3080101 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin injection therapy (controls)
Number of subjects: 12
Study 29966499 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally Adapted Behavioral Family Psycho‐Education Program (CA-BFPEP), 14 sessions
Number of subjects: 60
Study 29966499 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 60
Study 26244828 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (WBVT) for 5 weeks
Number of subjects: 2
Study 26244828 — intervention group
Group type: COMPARATOR
Intervention: Control group (identical exercises without vibration)
Number of subjects: 2
Study 24651243 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial cord stimulation with 40 mL of 0.5% ropivacaine
Number of subjects: 96
Study 24651243 — intervention group
Group type: COMPARATOR
Intervention: Posterior cord stimulation with 40 mL of 0.5% ropivacaine
Number of subjects: 96
Study 21673624 — intervention group
Group type: EXPERIMENTAL
Intervention: Jadad assessment tool
Number of subjects: 54
Study 21673624 — intervention group
Group type: EXPERIMENTAL
Intervention: van Tulder assessment tool
Number of subjects: 54
Study 21673624 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of Bias (RoB) assessment tool
Number of subjects: 54
Study 21673624 — intervention group
Group type: EXPERIMENTAL
Intervention: Jadad assessment tool for allocation concealment
Number of subjects: 54
Study 21673624 — intervention group
Group type: EXPERIMENTAL
Intervention: van Tulder assessment tool for allocation concealment
Number of subjects: 54
Study 21673624 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of Bias (RoB) for allocation concealment
Number of subjects: 54
Study 21673624 — intervention group
Group type: EXPERIMENTAL
Intervention: van Tulder assessment tool for sequence generation
Number of subjects: 54
Study 21673624 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of Bias (RoB) for sequence generation
Number of subjects: 54
Study 20685858 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 μg alum-formulated human recombinant GAD65
Number of subjects: 73
Study 20685858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 20685858 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 73
Study 18018993 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care + 6 x 6 exercises
Number of subjects: 45
Study 18018993 — intervention group
Group type: COMPARATOR
Intervention: Self-care
Number of subjects: 45
Study 16142556 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch colposuspension
Number of subjects: 50
Study 16142556 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension free vaginal tape (TVT)
Number of subjects: 50
Study 16142556 — intervention group
Group type: COMPARATOR
Intervention: TVT
Number of subjects: 50
Study 11161417 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothesis-testing training tasks
Number of subjects: 5
Study 11161417 — intervention group
Group type: COMPARATOR
Intervention: Memorization training tasks
Number of subjects: 5
Study 9008243 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention for 6 weeks
Number of subjects: 0
Study 9008243 — intervention group
Group type: COMPARATOR
Intervention: Measurements-only control group
Number of subjects: 0
Study 7984577 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriers of antigen HLA-DR2 and haptoglobin phenotype 2-2
Number of subjects: 84
Study 7984577 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of HLA-DR2 and haptoglobin phenotype 2-2
Number of subjects: 84
Study 7984577 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriers of HLA-DR2 and haptoglobin phenotype 2-2
Number of subjects: 84
Study 3549757 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education
Number of subjects: 532
Study 3549757 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician education
Number of subjects: 532
Study 3549757 — intervention group
Group type: EXPERIMENTAL
Intervention: Both patient and physician education
Number of subjects: 532
Study 3549757 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 532
Study 29285955 — intervention group
Group type: EXPERIMENTAL
Intervention: TIGRIS stent
Number of subjects: 274
Study 29285955 — intervention group
Group type: COMPARATOR
Intervention: LifeStent
Number of subjects: 274
Study 27102382 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive stents (BAS)
Number of subjects: 827
Study 27102382 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 827
Study 24034658 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated telephone call advising to have a walk-in BP check
Number of subjects: 64773
Study 24034658 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 64773
Study 21699720 — intervention group
Group type: EXPERIMENTAL
Intervention: Hibler's method
Number of subjects: 8
Study 21699720 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulance blankets / quilts
Number of subjects: 8
Study 21699720 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble wrap
Number of subjects: 8
Study 18714107 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor VIIa (recombinant)
Number of subjects: 0
Study 17060001 — intervention group
Group type: EXPERIMENTAL
Intervention: Coiled catheter
Number of subjects: 132
Study 17060001 — intervention group
Group type: COMPARATOR
Intervention: Straight catheter
Number of subjects: 132
Study 12947433 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (4 x 1 g) containing a natural carotenoid mixture (4 x 7.6 mg)
Number of subjects: 32
Study 12947433 — intervention group
Group type: COMPARATOR
Intervention: Fish oil (4 x 1 g)
Number of subjects: 32
Study 10702522 — intervention group
Group type: EXPERIMENTAL
Intervention: Storage at -70 degrees C
Number of subjects: 0
Study 9051365 — intervention group
Group type: COMPARATOR
Intervention: Conventional subcutaneous injection technique (with skin preparation)
Number of subjects: 50
Study 9051365 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental injection technique through clothing
Number of subjects: 50
Study 8398919 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer radiotherapy treatment schedule
Number of subjects: 63
Study 8398919 — intervention group
Group type: COMPARATOR
Intervention: Shorter radiotherapy treatment schedule
Number of subjects: 63
Study 8398919 — intervention group
Group type: EXPERIMENTAL
Intervention: Trait anxiety
Number of subjects: 63
Study 8398919 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping style
Number of subjects: 63
Study 3137773 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose disodium etidronate (EHDP) 5-7 mg/kg/day
Number of subjects: 29
Study 3137773 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose disodium etidronate (EHDP) plus 1 alpha-hydroxyvitamin D3 (1 alpha D3) 0.5 mcg daily
Number of subjects: 29